Details of the Drug-Related molecule(s) Interaction Atlas

Benzene sulfonamide derivative 16 Drug Info

PMID27414413-Compound-Figure3upright

Cross-matching ID

PubChem CID

46840946

CAS Number

CAS 1235403-62-9

TTD Drug ID

DMATBZW

General Information of Drug (ID: DMATBZW)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Urate anion exchanger 1 (URAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lesinurad	DMUR64T	Hyperuricaemia	5C55.Y	Approved	[2]
Dotinurad	DM0UPQJ	Gout	FA25	Phase 3	[3]
URC102	DMY89BN	Gout	FA25	Phase 2	[4]
RDEA-684	DMNWYHD	Gout	FA25	Phase 2	[2]
RDEA3170	DM1TKG4	Hyperuricaemia	5C55.Y	Phase 2	[5]
AR882	DMFGYZ8	Gout	FA25	Phase 2	[6]
Sulfonamide derivative 11	DMJBR86	N. A.	N. A.	Patented	[1]
Cycloalkyl acid derivative 1	DMXMGSP	N. A.	N. A.	Patented	[1]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1	DMHYIAV	N. A.	N. A.	Patented	[1]
Tihoacetate derivative 1	DM6QHO0	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
3	Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406.
4	Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
5	The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
6	Clinical pipeline report, company report or official report of Arthrosi Therapeutics